Cellectis (NASDAQ:CLLS) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS) in a research report released on Wednesday. The brokerage issued a sell rating on the biotechnology company’s stock.

CLLS has been the subject of several other reports. JMP Securities restated a market outperform rating and set a $6.00 price objective on shares of Cellectis in a research report on Friday, May 31st. Oppenheimer reduced their price objective on Cellectis from $11.00 to $10.00 and set an outperform rating on the stock in a research report on Wednesday, June 12th.

Cellectis Stock Down 1.7 %

Cellectis stock opened at $2.30 on Wednesday. Cellectis has a fifty-two week low of $0.96 and a fifty-two week high of $3.77. The firm has a market capitalization of $127.84 million, a price-to-earnings ratio of -1.78 and a beta of 3.09. The stock’s fifty day moving average is $2.19 and its two-hundred day moving average is $2.42. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.92 and a current ratio of 1.92.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.05. The firm had revenue of $9.50 million for the quarter, compared to analysts’ expectations of $6.00 million. Cellectis had a negative net margin of 401.83% and a negative return on equity of 78.90%. Analysts predict that Cellectis will post -0.54 EPS for the current fiscal year.

Hedge Funds Weigh In On Cellectis

A number of institutional investors have recently modified their holdings of CLLS. Long Focus Capital Management LLC grew its stake in Cellectis by 2.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after acquiring an additional 130,000 shares during the period. Principal Financial Group Inc. lifted its stake in shares of Cellectis by 6.2% during the 1st quarter. Principal Financial Group Inc. now owns 424,533 shares of the biotechnology company’s stock worth $1,125,000 after purchasing an additional 24,906 shares during the period. XTX Topco Ltd acquired a new stake in shares of Cellectis during the second quarter worth $29,000. Finally, Baillie Gifford & Co. grew its position in shares of Cellectis by 1.3% in the first quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company’s stock valued at $2,192,000 after purchasing an additional 10,605 shares during the period. Institutional investors and hedge funds own 63.90% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.